Seven Eight Capital, LP Arvinas, Inc. Transaction History

Seven Eight Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$24.46 - $40.4 $817,795 - $1.35 Million	33,434 Added 575.95%	39,239 $1.04 Million
Q1 2024 May 13, 2024	SELL	$36.38 - $52.31 $846,417 - $1.22 Million	-23,266 Reduced 80.03%	5,805 $239,000
Q4 2023 Feb 13, 2024	BUY	$14.19 - $42.33 $412,517 - $1.23 Million	29,071 New	29,071 $1.2 Million
Q2 2021 Aug 13, 2021	SELL	$60.45 - $84.26 $507,780 - $707,784	-8,400 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$20.19 - $84.93 $169,596 - $713,412	8,400 New	8,400 $713,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.